[日本語] English
文献
- EMDB/PDB/SASBDBから引用されている文献のデータベース -

+
検索条件

キーワード
構造解析手法
著者・登録者
ジャーナル
IF

-
Structure paper

タイトルCrystal Structure of a human FABP4 complex
ジャーナル・号・ページTo be published
掲載日2023年4月27日 (構造データの登録日)
著者Obst, U. / Magnone, C. / Kuhn, B. / Rudolph, M.G.
リンクPubMedで検索
手法X線回折
解像度0.88 - 2.6 Å
構造データ

PDB-7fvu:
Crystal Structure of human FABP4 in complex with 2-[2-(benzothiophen-3-yl)-2,3-dihydrobenzothiophene-3-carbonyl]benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.24 Å

PDB-7fvv:
Crystal Structure of human FABP4 in complex with (1S,2R)-2-[(5-carbamoyl-3-ethoxycarbonyl-4-methyl-2-thienyl)carbamoyl]cyclohexanecarboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7fvw:
Crystal Structure of human FABP4 in complex with 2-[2-(3-chlorophenyl)ethyl]-1,3-thiazole-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.04 Å

PDB-7fvx:
Crystal Structure of human FABP4 in complex with 4-(1-methyl-2-phenylindol-3-yl)cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fvy:
Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenyl)methyl]-1,3-thiazole-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1 Å

PDB-7fw0:
Crystal Structure of human FABP4 in complex with 3-methyl-2-(2,4,5-trichlorophenyl)sulfanylbutanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fw1:
Crystal Structure of human FABP4 in complex with 2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.26 Å

PDB-7fw2:
Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazole-3-thiol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fw3:
Crystal Structure of human FABP4 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7fw4:
Crystal Structure of human FABP4 soaked with glycerol
手法: X-RAY DIFFRACTION / 解像度: 1.44 Å

PDB-7fw5:
Crystal Structure of human FABP4 with active site mutated to that of FABP3 in complex with palmitate
手法: X-RAY DIFFRACTION / 解像度: 1.15 Å

PDB-7fw6:
Crystal Structure of human FABP4 in complex with 2-[(3-chlorophenoxy)methyl]-4-phenoxycyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.04 Å

PDB-7fw7:
Crystal Structure of human FABP4 in complex with 2-[(3-chloro-4-fluorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.06 Å

PDB-7fw9:
Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1 Å

PDB-7fwa:
Crystal Structure of human FABP4 in complex with 5-[(4-chloroanilino)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7fwb:
Crystal Structure of human FABP4 in complex with 5-[2-(2,4-dichlorophenoxy)phenyl]-1H-tetrazole
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwc:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-2-(hydroxymethylene)cyclohexane-1,3-dione
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwd:
Crystal Structure of human FABP4 in complex with 3-[1-(4-carbamoylphenyl)-5-(4-fluorophenyl)pyrrol-2-yl]propanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwe:
Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)sulfanylbutanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fwg:
Crystal Structure of human FABP4 in complex with 1-[(4-chloro-3-phenoxyphenyl)methyl]-4-hydroxypyridin-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.13 Å

PDB-7fwh:
Crystal Structure of human FABP4 in complex with 3-[5-(3,5-dichlorophenyl)tetrazol-2-yl]propanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwj:
Crystal Structure of human FABP4 in complex with 5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7fwk:
Crystal Structure of human FABP4 in complex with 1-[(2-chlorophenyl)methyl]pyrrole-2-carboxamide
手法: X-RAY DIFFRACTION / 解像度: 0.95 Å

PDB-7fwl:
Crystal Structure of human FABP4 in complex with 5-[(3,4-dichlorophenyl)methyl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwn:
Crystal Structure of human FABP4 in complex with 3-(5-methyl-2,3-diphenylindol-1-yl)propanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwo:
Crystal Structure of human FABP4 in complex with 2-cyclohexyl-6-hydroxy-1-benzofuran-3-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwp:
Crystal Structure of human FABP4 in complex with 3-hydroxy-4-[3-(3-methoxyphenyl)propyl]-2-(2-phenylethyl)-2H-furan-5-one
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7fwr:
Crystal Structure of human FABP4 in complex with 3-[(3,4-dichlorophenyl)methylsulfanyl]-1,2,4-triazin-5-ol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fws:
Crystal Structure of human FABP4 covalently modified with 1,2-benzothiazol-3-one
手法: X-RAY DIFFRACTION / 解像度: 1.1 Å

PDB-7fwu:
Crystal Structure of human FABP4 in complex with 2-(fluoren-9-ylidenemethyl)-4-hydroxy-2,3-dihydropyran-6-one
手法: X-RAY DIFFRACTION / 解像度: 1.01 Å

PDB-7fww:
Crystal Structure of human FABP4 in complex with (3-bromophenyl)-[(2Z)-2-phenylimino-1,3-thiazepan-3-yl]methanone
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fwy:
Crystal Structure of human FABP4 in complex with 2-[(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-6-yl)sulfanyl]acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fwz:
Crystal Structure of human FABP4 in complex with 4-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-4H-cyclohepta[c]pyrazol-1-yl]butanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fx0:
Crystal Structure of human FABP4 in complex with 5-[(2-chloroanilino)methyl]-4-ethyl-1,2,4-triazole-3-thiol
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7fx1:
Crystal Structure of human FABP4 in complex with 2-(3-phenyl-4-piperidin-1-ylphenyl)acetic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7fx4:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fx5:
Crystal Structure of human FABP4 in complex with 5-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fx6:
Crystal Structure of human FABP4 in complex with N,N-diethyl-4-pyridin-4-yl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-amine
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fx7:
Crystal Structure of human FABP4 with binding site mutated to FABP5 in complex with 5-methylsulfanyl-2-[(4-phenylmethoxy-1H-indazol-3-yl)methylsulfanyl]pyrimidin-4-ol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fx8:
Crystal Structure of human FABP4 in complex with 4-(2-methylpropyl)-2-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fx9:
Crystal Structure of human FABP4 in complex with 2-(3-cyanoanilino)benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.1 Å

PDB-7fxa:
Crystal Structure of human FABP4 in complex with 6-bromo-4-hexyl-2-oxo-1,3-dihydroquinoline-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fxb:
Crystal Structure of human FABP4 in complex with 2-methyl-2-(2,3,4,5,6-pentachlorophenoxy)propanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fxc:
Crystal Structure of human FABP4 in complex with 6-[(3,4-dichlorophenyl)methyl]-5-methyl-1,1-dioxo-1,2,6-thiadiazin-3-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fxe:
Crystal Structure of human FABP4 in complex with 2-(9-benzyl-6-methyl-1,2,3,4-tetrahydrocarbazol-1-yl)acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.04 Å

PDB-7fxf:
Crystal Structure of human FABP4 in complex with 2-[(2-chlorophenoxy)methyl]-1,3-thiazole-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 0.95 Å

PDB-7fxg:
Crystal Structure of human FABP4 in complex with 2-chloro-4,6-bis(trifluoromethylsulfanyl)phenol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fxh:
Crystal Structure of human FABP4 in complex with 2-[(2R)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fxi:
Crystal Structure of human FABP4 in complex with rac-(1R,3S)-2,2-dimethyl-3-[(2-phenylphenyl)carbamoyl]cyclopropane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.51 Å

PDB-7fxj:
Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-3,4-dihydroxy-2H-pyrrol-5-one
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7fxk:
Crystal Structure of human FABP4 in complex with 5-benzyl-4-(2,5-dimethylpyrrol-1-yl)-1,2,4-triazole-3-thiol
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7fxm:
Crystal Structure of human FABP4 in complex with 5-cyclohexyl-2-hydroxybenzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.19 Å

PDB-7fxn:
Crystal Structure of human FABP4 in complex with 2-[(2S)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fxp:
Crystal Structure of human FABP4 in complex with (Z)-4-(4-bromo-2-chloroanilino)-4-oxobut-2-enoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fxq:
Crystal Structure of human FABP4 in complex with 2-(5,6,7,8,9,10-hexahydrobenzo[8]annulen-3-yl)acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fxr:
Crystal Structure of human FABP4 in complex with 2-[rac-(9R,10S)-10-benzyl-3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-yl]acetic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7fxt:
Crystal Structure of human FABP4 in complex with N-(2,1,3-benzothiadiazol-4-yl)-2,5-dichlorothiophene-3-sulfonamide
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7fxu:
Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.96 Å

PDB-7fxv:
Crystal Structure of human FABP4 in complex with 6-[(4-methoxyphenyl)methyl]-2H-1,2,4-triazine-3,5-dithione
手法: X-RAY DIFFRACTION / 解像度: 0.88 Å

PDB-7fxw:
Crystal Structure of human FABP4 in complex with 5,6-dichloro-3-(2-chlorophenyl)-1H-indole-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.18 Å

PDB-7fxy:
Crystal Structure of human FABP4 in complex with (4-chlorophenyl)methyl 5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylate
手法: X-RAY DIFFRACTION / 解像度: 1.13 Å

PDB-7fxz:
Crystal Structure of human FABP4 in complex with 4-hexylsulfanyl-1-(3-pyridylmethyl)-6-sulfanyl-1,3,5-triazin-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7fy2:
Crystal Structure of human FABP4 in complex with 2-chloro-5-pyrrol-1-ylbenzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fy5:
Crystal Structure of human FABP4 in complex with 2,5,5-trimethyl-6,7,8,9-tetrahydrobenzo[7]annulene-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fy6:
Crystal Structure of human FABP4 in complex with 6-phenyl-11H-pyrimido[4,5-c][2]benzazepin-3-amine
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fy7:
Crystal Structure of human FABP4 in complex with 2-(indole-1-carbonylamino)benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fyb:
Crystal Structure of human FABP4 in complex with rac-(1R,2S,4R)-2-[(3-chlorobenzoyl)amino]-4-phenoxycyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fyc:
Crystal Structure of human FABP4 in complex with (2R)-1-[(2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7fye:
Crystal Structure of human FABP4 in complex with 1-[(4-chlorophenyl)methyl]-4-hydroxypyridin-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.25 Å

PDB-7fyf:
Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fyg:
Crystal Structure of human FABP4 in complex with 6-benzyl-2H-1,2,4-triazine-3,5-dithione
手法: X-RAY DIFFRACTION / 解像度: 0.94 Å

PDB-7fyi:
Crystal Structure of human FABP4 in complex with 5-[(4-chlorophenyl)sulfanylmethyl]-2-methylpyrazol-3-ol
手法: X-RAY DIFFRACTION / 解像度: 1.14 Å

PDB-7fyj:
Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
手法: X-RAY DIFFRACTION / 解像度: 2.6 Å

PDB-7fyk:
Crystal Structure of human FABP4 in complex with 5-phenylmethoxy-4-prop-2-enyl-1,2,4-triazole-3-thiol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fyl:
Crystal Structure of human FABP4 in complex with 6-(4-chlorophenyl)sulfanyl-2-(4-methylphenyl)sulfanylhexanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7fyo:
Crystal Structure of human FABP4 in complex with 5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fyp:
Crystal Structure of human FABP4 in complex with (1S,2S)-2-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxycarbonylcyclopropane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fyq:
Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fyr:
Crystal Structure of human FABP4 in complex with 5-(3,4-dichlorophenyl)-5-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fys:
Crystal Structure of human FABP4 in complex with 7-(4-methoxyphenyl)-1,8-dithia-3-azaspiro[4.5]dec-6-ene-2,4-dione
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fyt:
Crystal Structure of human FABP4 in complex with 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
手法: X-RAY DIFFRACTION / 解像度: 1.24 Å

PDB-7fyu:
Crystal Structure of human FABP4 in complex with 2-benzyl-6-tert-butyl-3-methyl-4-phenyl-5-(1H-tetrazol-5-yl)pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.17 Å

PDB-7fyv:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-9-methyl-3-oxa-4-azatricyclo[5.2.1.02,6]dec-4-ene-8-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 0.97 Å

PDB-7fyx:
Crystal Structure of human FABP4 in complex with 2-[(3-phenylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.4 Å

PDB-7fyy:
Crystal Structure of human FABP4 in complex with 5,7-bis(trifluoromethylsulfanyl)quinolin-8-ol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fyz:
Crystal Structure of human FABP4 in complex with 2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-methoxyacetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.13 Å

PDB-7fz0:
Crystal Structure of human FABP4 in complex with 2-tert-butyl-6-ethyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fz1:
Crystal Structure of human FABP4 in complex with 3-[(E)-anilino-(2-oxo-1H-indol-3-ylidene)methyl]sulfanylpropanoic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7fz2:
Crystal Structure of human FABP4 in complex with [3-oxo-5-[4-(trifluoromethyl)phenyl]cyclohexen-1-yl] acetate
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fz3:
Crystal Structure of human FABP4 in complex with 4-(4-chlorophenoxy)benzenesulfinic acid:sodium hydride
手法: X-RAY DIFFRACTION / 解像度: 1.1 Å

PDB-7fz4:
Crystal Structure of human FABP4 in complex with 6-(difluoromethyl)-4-isobutyl-5-methoxycarbonyl-2-(trifluoromethyl)pyridine-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.01 Å

PDB-7fz5:
Crystal Structure of human FABP4 in complex with rac-(2R)-1-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]pyrrolidine-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.25 Å

PDB-7fz6:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-(phenoxymethyl)cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.09 Å

PDB-7fz7:
Crystal Structure of human FABP4 in complex with 2-[2-[(2-chlorophenyl)methyl]-1-hydroxycyclohexyl]acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fz8:
Crystal Structure of human FABP4 in complex with thieno[2,3-d]pyrimidine-2,4-diamine
手法: X-RAY DIFFRACTION / 解像度: 1.22 Å

PDB-7fz9:
Crystal Structure of human FABP4 in complex with N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
手法: X-RAY DIFFRACTION / 解像度: 0.96 Å

PDB-7fzb:
Crystal Structure of human FABP4 in complex with 2-[5-methyl-2-(1-methylcyclohexyl)-1,3-oxazol-4-yl]acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7fzc:
Crystal Structure of human FABP4 in complex with 5-[(2-chlorophenoxy)methyl]-4-propan-2-yl-1,2,4-triazole-3-thiol
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzd:
Crystal Structure of human FABP4 in complex with 3-(4-chlorophenyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,2]oxazole-5-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7fzf:
Crystal Structure of human FABP4 in complex with 2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3-yl)butanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.09 Å

PDB-7fzh:
Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-5,7-dihydro-4H-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzi:
Crystal Structure of human FABP4 in complex with 2-[[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7fzj:
Crystal Structure of human FABP4 in complex with 3-cyclohexyl-2-ethylsulfanyl-6-hydroxypyrimidin-4-one
手法: X-RAY DIFFRACTION / 解像度: 1.25 Å

PDB-7fzl:
Crystal Structure of human FABP4 in complex with 3-(3-chlorophenyl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzm:
Crystal Structure of human FABP4 in complex with N-(2,4-dichlorophenyl)-2-(2,6-dihydroxypyrimidin-4-yl)acetamide
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7fzn:
Crystal Structure of human FABP4 in complex with (1S,2S,5R)-3-(2-thiophen-3-ylacetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzo:
Crystal Structure of human FABP4 in complex with 4-oxo-3-(2-phenylethyl)-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7fzp:
Crystal Structure of human FABP4 in complex with 6-[(4-chlorophenyl)methylsulfanylmethyl]-2-sulfanylidene-1H-pyrimidin-4-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzr:
Crystal Structure of human FABP4 in complex with 4-hydroxy-6-(2-naphthalen-1-ylethyl)pyran-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7fzs:
Crystal Structure of human FABP4 in complex with 6-chloro-4-[(2-chlorophenyl)methyl]-2-methylquinoline-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.04 Å

PDB-7fzv:
Crystal Structure of human FABP4 in complex with 1-[(2,4-dichlorophenyl)methyl]-4-hydroxy-3-[(E)-3-phenylprop-2-enyl]pyridin-2-one
手法: X-RAY DIFFRACTION / 解像度: 2.55 Å

PDB-7fzw:
Crystal Structure of human FABP4 in complex with 2-[[5-bromo-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.24 Å

PDB-7fzx:
Crystal Structure of human FABP4 in complex with (2S)-6-(4-chlorophenoxy)-2-(4-methylphenoxy)hexanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7fzy:
Crystal Structure of human FABP4 in complex with 6-chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)quinoline
手法: X-RAY DIFFRACTION / 解像度: 1.17 Å

PDB-7fzz:
Crystal Structure of human FABP4 in complex with 3-[(2,4-dichloro-5-methylphenyl)sulfonylamino]thiophene-2-carboxamide
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g02:
Crystal Structure of human FABP4 in complex with 7-methoxy-1-(3-methoxyphenyl)naphthalene-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7g03:
Crystal Structure of human FABP4 in complex with 6-fluoro-1,3-benzothiazol-2-amine
手法: X-RAY DIFFRACTION / 解像度: 1.27 Å

PDB-7g05:
Crystal Structure of human FABP4 in complex with 2,6-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenol
手法: X-RAY DIFFRACTION / 解像度: 0.95 Å

PDB-7g06:
Crystal Structure of human FABP4 in complex with 5-(chloromethyl)-2-phenyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
手法: X-RAY DIFFRACTION / 解像度: 1.26 Å

PDB-7g07:
Crystal Structure of human FABP4 in complex with 4-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]-3,6-dihydro-2H-pyran-5-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.61 Å

PDB-7g08:
Crystal Structure of human FABP4 in complex with 2-(3-chloro-2-methylanilino)benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7g09:
Crystal Structure of human FABP4 in complex with 8-(3-bromophenyl)-7,9-dioxa-1-thia-3-azaspiro[4.5]decane-2,4-dione
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7g0a:
Crystal Structure of human FABP4 in complex with 5-(6-chloro-4-phenyl-2-piperidin-1-ylquinolin-3-yl)-3H-1,3,4-oxadiazol-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g0f:
Crystal Structure of human FABP4 in complex with 6-[(3-methoxycarbonyl-4-thiophen-2-ylthiophen-2-yl)carbamoyl]cyclohex-3-ene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g0g:
Crystal Structure of human FABP4 in complex with 5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g0h:
Crystal Structure of human FABP4 in complex with (2R,3S)-2-(phenoxymethyl)-1-phenyl-pyrrolidine-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.46 Å

PDB-7g0i:
Crystal Structure of human FABP4 in complex with 5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.07 Å

PDB-7g0j:
Crystal Structure of human FABP4 in complex with 2-[3-(4-chloro-2-phenoxyphenyl)phenyl]acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7g0k:
Crystal Structure of human FABP4 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.13 Å

PDB-7g0l:
Crystal Structure of human FABP4 in complex with 3-[(4-methyl-3-phenoxyphenyl)methyl]-1H-pyrazol-5-ol
手法: X-RAY DIFFRACTION / 解像度: 1.18 Å

PDB-7g0m:
Crystal Structure of human FABP4 in complex with 2-tert-butylsulfanyl-6-phenyl-1H-1,3,5-triazine-4-thione
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7g0p:
Crystal Structure of human FABP4 in complex with 3-[(4-phenyl-5-sulfanylidene-1,3,4-thiadiazol-2-yl)sulfanyl]propane-1-sulfonic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7g0q:
Crystal Structure of human FABP4 in complex with 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7g0r:
Crystal Structure of human FABP4 in complex with 4-methoxy-1,2-benzoxazol-3-amine
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7g0s:
Crystal Structure of human FABP4 in complex with 2,3-bis(phenylmethoxy)benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7g0t:
Crystal Structure of human FABP4 in complex with 1-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.65 Å

PDB-7g0u:
Crystal Structure of human FABP4 in complex with 5-[(3-chlorophenyl)methyl]-6-hydroxy-1-methyl-4-morpholin-4-ylpyrimidin-2-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g0v:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[[3-(trifluoromethyl)phenoxy]methyl]cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.06 Å

PDB-7g0y:
Crystal Structure of human FABP4 in complex with 2-(2-methoxyanilino)benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 0.99 Å

PDB-7g11:
Crystal Structure of human FABP4 in complex with 2,4,6-triisopropylbenzenesulfonic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g14:
Crystal Structure of human FABP4 in complex with 6-cyclopentyl-N,5-dimethyl-4-phenyl-N-propan-2-yl-3-(1H-tetrazol-5-yl)pyridin-2-amine
手法: X-RAY DIFFRACTION / 解像度: 1.2 Å

PDB-7g16:
Crystal Structure of human FABP4 in complex with 6-bromo-3-hexyl-2-oxo-3,4-dihydro-1H-quinoline-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.1 Å

PDB-7g17:
Crystal Structure of human FABP4 in complex with 2-(1H-indol-7-yloxymethyl)-1,3-thiazole-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.05 Å

PDB-7g18:
Crystal Structure of human FABP4 in complex with 4-(4-chloro-3-fluorophenoxy)-2-(3,4-dichlorophenyl)-2-methylbutanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g19:
Crystal Structure of human FABP4 in complex with 5-[2-(1H-tetrazol-5-yl)ethyl]-6,7,8,9,10,11-hexahydrocycloocta[b]indole
手法: X-RAY DIFFRACTION / 解像度: 1.04 Å

PDB-7g1a:
Crystal Structure of human FABP4 in complex with 2-[(3S)-oxolan-3-yl]oxy-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g1b:
Crystal Structure of human FABP4 in complex with 2-[1-[(3-chlorophenyl)methyl]indol-2-yl]cyclopropane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.17 Å

PDB-7g1c:
Crystal Structure of human FABP4 in complex with rac-(1R,2S)-2-[(3-methylphenoxy)methyl]cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7g1d:
Crystal Structure of human FABP4 in complex with 5-ethyl-6-(3-methoxyphenyl)-3-methyl-2-sulfanylidene-1H-pyrimidin-4-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g1e:
Crystal Structure of human FABP4 in complex with 3-[(2-phenylphenoxy)methyl]benzoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.21 Å

PDB-7g1f:
Crystal Structure of human FABP4 in complex with 1-(4-methylphenyl)sulfonyl-3-(8-tricyclo[5.2.1.02,6]decanyl)urea
手法: X-RAY DIFFRACTION / 解像度: 0.91 Å

PDB-7g1g:
Crystal Structure of human FABP4 in complex with 2-(2-hydroxy-3,5,5,8,8-pentamethyl-3,4,4a,6,7,8a-hexahydro-1H-naphthalen-2-yl)acetic acid
手法: X-RAY DIFFRACTION / 解像度: 1.03 Å

PDB-7g1h:
Crystal Structure of human FABP4 in complex with 2-(3,5-ditert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g1i:
Crystal Structure of human FABP4 in complex with 5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.53 Å

PDB-7g1j:
Crystal Structure of human FABP4 in complex with 2-[[3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl]cyclohexene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.11 Å

PDB-7g1k:
Crystal Structure of human FABP4 in complex with 4-(4-fluorophenyl)sulfanyl-6-methyl-2-phenylpyrimidine-5-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g1l:
Crystal Structure of human FABP4 in complex with 6-(1,3-benzodioxol-5-ylmethyl)-3-sulfanyl-1,2,4-triazin-5-ol
手法: X-RAY DIFFRACTION / 解像度: 0.98 Å

PDB-7g1n:
Crystal Structure of human FABP4 in complex with rac-(1R,2R)-2-[[3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]cyclohexane-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.55 Å

PDB-7g1o:
Crystal Structure of human FABP4 in complex with 4-chloro-2,5-dimethyl-N-(2-methylpyrazol-3-yl)benzenesulfonamide
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g1r:
Crystal Structure of human FABP4 in complex with 2-[(3-ethoxycarbonylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 0.93 Å

PDB-7g1s:
Crystal Structure of human FABP4 in complex with 3-(3,4-dichlorophenyl)-3,7a-dihydro-1H-imidazo[1,5-c][1,3]thiazole-5,7-dione
手法: X-RAY DIFFRACTION / 解像度: 1.08 Å

PDB-7g1t:
Crystal Structure of human FABP4 in complex with 6-methyl-3-phenyl-1,2,4-triazin-5-ol
手法: X-RAY DIFFRACTION / 解像度: 1.1 Å

PDB-7g1u:
Crystal Structure of human FABP4 in complex with 2-[[5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.14 Å

PDB-7g1v:
Crystal Structure of human FABP4 in complex with 3-[(2-sulfanylphenyl)carbamoyl]bicyclo[2.2.1]heptane-2-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 1.02 Å

PDB-7g1y:
Crystal Structure of human FABP4 in complex with 2-[(3-methoxyphenyl)sulfanylmethyl]-1,3-thiazole-4-carboxylic acid
手法: X-RAY DIFFRACTION / 解像度: 0.95 Å

PDB-7g1z:
Crystal Structure of human FABP4 in complex with 5-[(4-chloro-3-phenoxyphenyl)methyl]-1H-tetrazole
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g20:
Crystal Structure of human FABP4 in complex with 1-[(4-methoxyphenyl)methyl]-5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-7g21:
Crystal Structure of human FABP4 in complex with 4-hydroxy-2-[(E)-2-(2-phenylcyclohexyl)ethenyl]-2,3-dihydropyran-6-one
手法: X-RAY DIFFRACTION / 解像度: 1.12 Å

PDB-8s1k:
Crystal Structure of human FABP4 in complex with 2-[1-(methoxymethyl)cyclopentyl]-6-pentyl-4-phenyl-3-(1H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline
手法: X-RAY DIFFRACTION / 解像度: 1.22 Å

化合物

ChemComp-SO4:
SULFATE ION / 硫酸ジアニオン

ChemComp-GFS:
2-[(2S,3R)-2,3-dihydro[2,3'-bi-1-benzothiophene]-3-carbonyl]benzoic acid

ChemComp-HOH:
WATER

ChemComp-IOV:
(1R,2S)-2-{[5-carbamoyl-3-(ethoxycarbonyl)-4-methylthiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-IQH:
2-[2-(3-chlorophenyl)ethyl]-1,3-thiazole-4-carboxylic acid

ChemComp-FMT:
FORMIC ACID / ギ酸

ChemComp-IUT:
(1s,4s)-4-(1-methyl-2-phenyl-1H-indol-3-yl)cyclohexane-1-carboxylic acid

ChemComp-IWI:
2-[(3-chlorophenyl)methyl]-1,3-thiazole-4-carboxylic acid

ChemComp-K0U:
(2R)-3-methyl-2-[(2,4,5-trichlorophenyl)sulfanyl]butanoic acid

ChemComp-K7C:
(5P)-2-cyclopentyl-4-(4-fluorophenyl)-6-[1-(methoxymethyl)cyclopentyl]-3-methyl-5-(1H-tetrazol-5-yl)pyridine

ChemComp-KCV:
5-[(4-chlorophenoxy)methyl]-4-(prop-2-en-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-DMS:
DIMETHYL SULFOXIDE / 2-チアプロパン2-オキシド / DMSO, 沈殿剤*YM

ChemComp-KL3:
(1R)-7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid

ChemComp-GOL:
GLYCEROL / グリセロ-ル

ChemComp-PLM:
PALMITIC ACID / パルミチン酸

ChemComp-KLX:
(1R,2S,4S)-2-[(3-chlorophenoxy)methyl]-4-phenoxycyclohexane-1-carboxylic acid

ChemComp-KWX:
(1S,2S)-2-[(3-chloro-4-fluorophenyl)carbamoyl]cyclohexane-1-carboxylic acid

ChemComp-L8T:
2-{[3-(ethoxycarbonyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-LE5:
(8S)-5-[(4-chloroanilino)methyl]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-LM9:
(5P)-5-[2-(2,4-dichlorophenoxy)phenyl]-2H-tetrazole

ChemComp-M69:
(2seqTrans,5S)-5-(4-chlorophenyl)-2-(hydroxymethylidene)cyclohexane-1,3-dione

ChemComp-M8I:
3-[1-(4-carbamoylphenyl)-5-(4-fluorophenyl)-1H-pyrrol-2-yl]propanoic acid

ChemComp-MF9:
(3S)-3-[(4-chlorophenyl)sulfanyl]butanoic acid

ChemComp-MWR:
1-[(4-chloro-3-phenoxyphenyl)methyl]-4-hydroxypyridin-2(1H)-one

ChemComp-N1I:
3-[5-(3,5-dichlorophenyl)-2H-tetrazol-2-yl]propanoic acid

ChemComp-MQF:
5-cyclohexyl-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-76Y:
1-[(2-chlorophenyl)methyl]pyrrole-2-carboxamide

ChemComp-O6Q:
5-[(3,4-dichlorophenyl)methyl]-1lambda~6~,2,5-thiadiazolidine-1,1,3-trione

ChemComp-OKF:
3-(5-methyl-2,3-diphenyl-1H-indol-1-yl)propanoic acid

ChemComp-OM6:
(2S)-2-cyclohexyl-6-hydroxy-1-benzofuran-3(2H)-one

ChemComp-OT9:
(5R)-4-hydroxy-3-[3-(3-methoxyphenyl)propyl]-5-(2-phenylethyl)furan-2(5H)-one

ChemComp-P6X:
3-{[(3,4-dichlorophenyl)methyl]sulfanyl}-1,2,4-triazin-5-ol

ChemComp-PV6:
2-sulfanylbenzamide / 2-メルカプトベンズアミド

ChemComp-Q0O:
(6S)-6-{[(4aM)-9H-fluoren-9-ylidene]methyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one

ChemComp-Q6I:
(3-bromophenyl)[(2Z)-2-(phenylimino)-1,3-thiazepan-3-yl]methanone

ChemComp-QBX:
{[(10R)-2-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl]sulfanyl}acetic acid

ChemComp-QD3:
4-[3-(trifluoromethyl)-5,6,7,8-tetrahydrocyclohepta[c]pyrazol-1(4H)-yl]butanoic acid

ChemComp-QG0:
5-[(2-chloroanilino)methyl]-4-ethyl-4H-1,2,4-triazole-3-thiol

ChemComp-QJD:
[6-(piperidin-1-yl)[1,1'-biphenyl]-3-yl]acetic acid

ChemComp-Q29:
(1R,2S)-2-[(3,4-dichlorophenoxy)methyl]cyclohexane-1-carboxylic acid

ChemComp-Q4X:
5-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-3,6-dihydro-2H-pyran-4-carboxylic acid

ChemComp-CL:
Unknown entry / クロリド

ChemComp-QJX:
(3M)-N,N-diethyl-4-(pyridin-4-yl)-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-amine

ChemComp-QLL:
2-({[4-(benzyloxy)-1H-indazol-3-yl]methyl}sulfanyl)-5-(methylsulfanyl)pyrimidin-4-ol

ChemComp-EDO:
1,2-ETHANEDIOL / エチレングリコ-ル

ChemComp-QN6:
(3M)-4-(2-methylpropyl)-2-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-QX0:
2-(3-cyanoanilino)benzoic acid / 2-[(3-シアノフェニル)アミノ]安息香酸

ChemComp-QYP:
(4S)-6-bromo-4-hexyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid

ChemComp-QZI:
2-methyl-2-(pentachlorophenoxy)propanoic acid

ChemComp-R80:
(5S)-6-[(3,4-dichlorophenyl)methyl]-5-methyl-1lambda~6~,2,6-thiadiazinane-1,1,3-trione

ChemComp-R9C:
[(1S)-9-benzyl-6-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid

ChemComp-R9O:
2-[(2-chlorophenoxy)methyl]-1,3-thiazole-4-carboxylic acid

ChemComp-RG6:
2-chloro-4,6-bis[(trifluoromethyl)sulfanyl]phenol

ChemComp-RI4:
(3P)-2-[(2R)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-RJM:
(1S,3R)-3-[([1,1'-biphenyl]-2-yl)carbamoyl]-2,2-dimethylcyclopropane-1-carboxylic acid

ChemComp-S4I:
(3S)-1-[(4-chlorophenyl)methyl]-3-hydroxypyrrolidine-2,4-dione

ChemComp-S8X:
5-benzyl-4-(2,5-dimethyl-1H-pyrrol-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-KWB:
5-cyclohexyl-2-hydroxybenzoate

ChemComp-SUX:
(3P)-2-[(2S)-oxolan-2-yl]-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-TB3:
(2Z)-4-(4-bromo-2-chloroanilino)-4-oxobut-2-enoic acid

ChemComp-TK6:
(5,6,7,8,9,10-hexahydrobenzo[8]annulen-2-yl)acetic acid

ChemComp-TQO:
[(8R,9S)-8-benzyl-3,3-dimethyl-1,5-dioxaspiro[5.5]undecan-9-yl]acetic acid

ChemComp-TZJ:
N-(2,1,3-benzothiadiazol-4-yl)-2,5-dichlorothiophene-3-sulfonamide

ChemComp-U6O:
2-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-U8H:
6-[(4-methoxyphenyl)methyl]-1,2,4-triazine-3,5(2H,4H)-dithione

ChemComp-UB8:
(3M)-5,6-dichloro-3-(2-chlorophenyl)-1H-indole-2-carboxylic acid

ChemComp-UKN:
(4-chlorophenyl)methyl 5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate

ChemComp-UO3:
4-hexylsulfanyl-1-(pyridin-3-ylmethyl)-6-sulfanyl-1$l^{4},3,5-triazacyclohexa-1,3,5-trien-2-ol

ChemComp-UOR:
2-chloro-5-(1H-pyrrol-1-yl)benzoic acid / 2-クロロ-5-(1H-ピロ-ル-1-イル)安息香酸

ChemComp-V4R:
3,9,9-trimethyl-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid

ChemComp-VI0:
(10S)-10-phenyl-10,11-dihydro-5H-pyrimido[4,5-c][2]benzazepin-2-amine

ChemComp-NC0:
2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid

ChemComp-VIY:
(1R,2S,4R)-2-(3-chlorobenzamido)-4-phenoxycyclohexane-1-carboxylic acid

ChemComp-VJ3:
1-[([1,1'-biphenyl]-2-yl)carbamoyl]-D-proline

ChemComp-VMN:
1-[(4-chlorophenyl)methyl]-4-hydroxypyridin-2(1H)-one

ChemComp-VS5:
(3M)-4-(4-fluorophenyl)-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine

ChemComp-VVL:
6-benzyl-1,2,4-triazine-3,5(2H,4H)-dithione

ChemComp-W7U:
(5R)-3-{[(4-chlorophenyl)sulfanyl]methyl}-1-methyl-4,5-dihydro-1H-pyrazol-5-ol

ChemComp-W7Z:
(8S)-5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-W8C:
5-(benzyloxy)-4-(prop-2-en-1-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-W8H:
(2S)-6-[(4-chlorophenyl)sulfanyl]-2-[(4-methylphenyl)sulfanyl]hexanoic acid

ChemComp-W90:
5-(3,5-dichloroanilino)-3,3-dimethyl-5-oxopentanoic acid

ChemComp-W95:
(1S,2S)-2-({[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]oxy}carbonyl)cyclopropane-1-carboxylic acid

ChemComp-W9B:
(2R)-2-(3,5-di-tert-butyl-2-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxypropanoic acid

ChemComp-W9F:
5-(3,4-dichlorophenyl)-5-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione

ChemComp-W9K:
(5R)-7-(4-hydroxyphenyl)-1,8-dithia-3-azaspiro[4.5]dec-6-ene-2,4-dione

ChemComp-UUX:
(2R,3S,4S)-6-benzyl-2-tert-butyl-5-methyl-4-phenyl-3-(1H-tetrazol-5-yl)-1,2,3,4-tetrahydropyridine

ChemComp-W9Q:
(3aR,4R,5R,6S,7R,7aR)-3-(4-chlorophenyl)-6-methyl-3a,4,5,6,7,7a-hexahydro-4,7-methano-1,2-benzoxazole-5-carboxylic acid

ChemComp-W9W:
2-{[(4R)-4-phenyl-3,4-dihydro-2H-1lambda~4~-thiophen-5-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WA4:
5,7-bis[(trifluoromethyl)sulfanyl]quinolin-8-ol

ChemComp-WA9:
(2R)-{2,3-bis[(2-chlorophenyl)methoxy]phenyl}(methoxy)acetic acid

ChemComp-EOH:
ETHANOL / エタノ-ル

ChemComp-WBR:
(3P)-2-tert-butyl-6-ethyl-4,5-diphenyl-3-(1H-tetrazol-5-yl)pyridine

ChemComp-WDE:
3-{[(E)-anilino(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]sulfanyl}propanoic acid

ChemComp-WDI:
(1S)-5-hydroxy-4'-(trifluoromethyl)-1,6-dihydro[1,1'-biphenyl]-3(2H)-one

ChemComp-WDO:
1-[bis(oxidanyl)-$l^{3}-sulfanyl]-4-(4-chloranylphenoxy)benzene

ChemComp-WE2:
6-(difluoromethyl)-5-(methoxycarbonyl)-4-(2-methylpropyl)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WE6:
1-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-D-proline

ChemComp-WEA:
(1S,2R)-2-(phenoxymethyl)cyclohexane-1-carboxylic acid

ChemComp-WED:
{(1R,2S)-2-[(2-chlorophenyl)methyl]-1-hydroxycyclohexyl}acetic acid

ChemComp-WEI:
thieno[2,3-d]pyrimidine-2,4-diamine

ChemComp-WER:
(3M,6P)-N-methyl-6-(3-methylthiophen-2-yl)-4-phenyl-N-(propan-2-yl)-3-(1H-tetrazol-5-yl)pyridin-2-amine

ChemComp-WEN:
[5-methyl-2-(1-methylcyclohexyl)-1,3-oxazol-4-yl]acetic acid / AD-4610

ChemComp-WF6:
5-[(2-chlorophenoxy)methyl]-4-(propan-2-yl)-4H-1,2,4-triazole-3-thiol

ChemComp-WFC:
(3aS,5R,6aS)-3-(4-chlorophenyl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,2]oxazole-5-carboxylic acid

ChemComp-WFK:
(1R,3R,4S)-3-(4-chlorobenzoyl)-4-hydroxycyclopentane-1-carboxylic acid

ChemComp-WFO:
(2R)-2-(6-methyl-4-oxo-5-phenylthieno[2,3-d]pyrimidin-3(4H)-yl)butanoic acid

ChemComp-WFX:
4-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6,6-difluoro-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-5,6-dihydro-2H-pyran-3-carboxylic acid

ChemComp-WG3:
2-{[(2M)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WGL:
1-cyclohexyl-2-(ethylsulfanyl)pyrimidine-4,6(1H,5H)-dione

ChemComp-WGQ:
(5P)-5-(3-chlorophenyl)-4-(prop-2-en-1-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

ChemComp-WGW:
N-(2,4-dichlorophenyl)-2-(2,6-dioxo-1,2,5,6-tetrahydropyrimidin-4-yl)acetamide

ChemComp-WHB:
(1R,2S,5S)-3-[(thiophen-3-yl)acetyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid

ChemComp-WH3:
(3aR,6S,7R,7aS)-1-oxo-2-(2-phenylethyl)-1,2,3,6,7,7a-hexahydro-3a,6-epoxyisoindole-7-carboxylic acid

ChemComp-WHI:
6-({[(4-chlorophenyl)methyl]sulfanyl}methyl)-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one

ChemComp-WHN:
4-hydroxy-6-[2-(naphthalen-1-yl)ethyl]-2H-pyran-2-one

ChemComp-WHR:
6-chloro-4-[(2-chlorophenyl)methyl]-2-methylquinoline-3-carboxylic acid

ChemComp-O1L:
1-[(2,4-dichlorophenyl)methyl]-4-hydroxy-3-[(2E)-3-phenylprop-2-en-1-yl]pyridin-2(1H)-one

ChemComp-WI8:
2-{[(2M)-5-bromo-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-BR:
BROMIDE ION / ブロミド

ChemComp-WIC:
(2S)-6-(4-chlorophenoxy)-2-(4-methylphenoxy)hexanoic acid

ChemComp-65X:
6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline

ChemComp-TRS:
2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL / トリス(ヒドロキシメチル)メチルアンモニウム / pH緩衝剤*YM

ChemComp-WIF:
3-[(2,4-dichloro-5-methylbenzene-1-sulfonyl)amino]thiophene-2-carboxamide

ChemComp-WIL:
(1M)-7-methoxy-1-(3-methoxyphenyl)naphthalene-2-carboxylic acid

ChemComp-PG4:
TETRAETHYLENE GLYCOL / テトラエチレングリコ-ル / 沈殿剤*YM

ChemComp-FBB:
6-fluoro-1,3-benzothiazol-2-amine / 6-フルオロベンゾチアゾ-ル-2-アミン

ChemComp-WJ3:
2,6-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenol

ChemComp-WJ8:
(8S)-5-(chloromethyl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one

ChemComp-WJH:
4-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}-5,6-dihydro-2H-pyran-3-carboxylic acid

ChemComp-TLF:
2-[(3-chloro-2-methylphenyl)amino]benzoic acid / トルフェナム酸 / 抗炎症剤, 阻害剤*YM

ChemComp-WJQ:
(5s,8s)-8-(3-bromophenyl)-7,9-dioxa-1-thia-3-azaspiro[4.5]decane-2,4-dione

ChemComp-WJU:
(5M)-5-[6-chloro-4-phenyl-2-(piperidin-1-yl)quinolin-3-yl]-1,3,4-oxadiazol-2(3H)-one

ChemComp-WK9:
(1R,2S)-2-{[(2M)-4'-(methoxycarbonyl)-4,5-dihydro-2'H,3H-[2,3'-bi-1lambda~4~-thiophen]-5'-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-W8N:
5-(3-bromo-4-methylphenyl)-3,3-dimethyl-5-oxopentanoic acid

ChemComp-W8T:
(2R,3S)-2-(phenoxymethyl)-1-phenylpyrrolidine-3-carboxylic acid

ChemComp-TXO:
5-phenoxy-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WKI:
[(1M)-4'-chloro-2'-phenoxy[1,1'-biphenyl]-3-yl]acetic acid

ChemComp-UOF:
1-[(4,6-dichloro[1,1'-biphenyl]-2-yl)carbamoyl]-D-proline

ChemComp-WKN:
3-[(4-methyl-3-phenoxyphenyl)methyl]-1H-pyrazol-5-ol

ChemComp-WKR:
4-(tert-butylsulfanyl)-6-phenyl-1,3,5-triazine-2(5H)-thione

ChemComp-WL0:
3-[(4-phenyl-5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)sulfanyl]propane-1-sulfonic acid

ChemComp-WL6:
4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid

ChemComp-5WX:
4-methoxy-1,2-benzoxazol-3-amine / 4-メトキシ-1,2-ベンゾイソオキサゾ-ル-3-アミン

ChemComp-UNU:
BENZAMIDE / ベンズアミド

ChemComp-WLB:
2,3-bis(benzyloxy)benzoic acid / 2,3-ビス(ベンジルオキシ)安息香酸

ChemComp-WLF:
1-{[4-chloro-2-(trifluoromethyl)phenyl]carbamamido}cyclopentane-1-carboxylic acid

ChemComp-WLN:
5-[(3-chlorophenyl)methyl]-6-hydroxy-1-methyl-4-(morpholin-4-yl)pyrimidin-2(1H)-one

ChemComp-WLR:
(1S,2R)-2-{[3-(trifluoromethyl)phenoxy]methyl}cyclohexane-1-carboxylic acid

ChemComp-WM5:
2-(2-methoxyanilino)benzoic acid / 2-(2-メトキシフェニルアミノ)安息香酸

ChemComp-75D:
2,4,6-tri(propan-2-yl)benzenesulfonic acid / 2,4,6-トリイソプロピルベンゼンスルホン酸

ChemComp-Q1I:
(3P)-6-cyclopentyl-N,5-dimethyl-4-phenyl-N-(propan-2-yl)-3-(1H-tetrazol-5-yl)pyridin-2-amine

ChemComp-WML:
(3S,4R)-6-bromo-3-hexyl-2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid

ChemComp-WMQ:
2-{[(1H-indol-7-yl)oxy]methyl}-1,3-thiazole-4-carboxylic acid

ChemComp-WMW:
(2S)-4-(4-chloro-3-fluorophenoxy)-2-(3,4-dichlorophenyl)-2-methylbutanoic acid

ChemComp-WN0:
5-[2-(1H-tetrazol-5-yl)ethyl]-6,7,8,9,10,11-hexahydro-5H-cycloocta[b]indole

ChemComp-WN5:
(3M)-2-{[(3S)-oxolan-3-yl]oxy}-4-phenyl-3-(1H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine

ChemComp-WNB:
(1S,2S)-2-{1-[(3-chlorophenyl)methyl]-1H-indol-2-yl}cyclopropane-1-carboxylic acid

ChemComp-WNF:
(1S,2R)-2-[(3-methylphenoxy)methyl]cyclohexane-1-carboxylic acid

ChemComp-WNL:
(6M)-5-ethyl-6-(3-methoxyphenyl)-3-methyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one

ChemComp-WNR:
3-{[([1,1'-biphenyl]-2-yl)oxy]methyl}benzoic acid

ChemComp-WNW:
4-methyl-N-{[(3aR,4R,5R,7R,7aR)-octahydro-1H-4,7-methanoinden-5-yl]carbamoyl}benzene-1-sulfonamide

ChemComp-WO0:
[(2S,3S,4aR,8aR)-2-hydroxy-3,5,5,8,8-pentamethyldecahydronaphthalen-2-yl]acetic acid

ChemComp-WOB:
5-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-2-(trifluoromethyl)pyridine-3-carboxylic acid

ChemComp-WKW:
2-{[(3M)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dimethylthiophen-2-yl]carbamoyl}cyclohex-1-ene-1-carboxylic acid

ChemComp-WOI:
4-[(4-fluorophenyl)sulfanyl]-6-methyl-2-phenylpyrimidine-5-carboxylic acid

ChemComp-WON:
6-[(2H-1,3-benzodioxol-5-yl)methyl]-3-sulfanyl-1,2,4-triazin-5-ol / 6-(1,3-ベンゾジオキソ-ル-5-イルメチル)-3-メルカプト-1,2,4-トリアジン-5(4H)-オン

ChemComp-WP0:
(1R,2R)-2-{[(3M)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid

ChemComp-WP8:
4-chloro-2,5-dimethyl-N-(1-methyl-1H-pyrazol-5-yl)benzene-1-sulfonamide

ChemComp-WPQ:
2-{[3-(ethoxycarbonyl)thiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WPU:
(3R,4R,7aS)-3-(3,4-dichlorophenyl)-1H,3H-imidazo[1,5-c][1,3]thiazole-5,7(6H,7aH)-dione

ChemComp-WPZ:
6-methyl-3-phenyl-1,2,4-triazin-5-ol / 3-フェニル-6-メチル-1,2,4-トリアジン-5(4H)-オン

ChemComp-WQ3:
2-{[(2M)-5-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid

ChemComp-WQ8:
(1R,2R,3R,4S)-3-(1,3-benzothiazol-2-yl)bicyclo[2.2.1]heptane-2-carboxylic acid

ChemComp-WQC:
2-{[(3-methoxyphenyl)sulfanyl]methyl}-1,3-thiazole-4-carboxylic acid

ChemComp-WQH:
5-[(4-methyl-3-phenoxyphenyl)methyl]-1H-tetrazole

ChemComp-WQL:
(5S)-1-[(4-methoxyphenyl)methyl]-5-(propan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

ChemComp-IKQ:
(6R)-4-hydroxy-6-{(E)-2-[(1R,2S)-2-phenylcyclohexyl]ethenyl}-5,6-dihydro-2H-pyran-2-one

PDB-1h4y:
Structure of the Anti-Sigma Factor Antagonist SpoIIAA in its Unphosphorylated Form

由来
  • homo sapiens (ヒト)
キーワードLIPID BINDING PROTEIN / FATTY ACID BINDING PROTEIN / CYTOPLASM / LIPID-BINDING / TRANSPORT / PROTEIN BINDING / HUMAN FABP4 / INHIBITOR

+
万見文献について

-
お知らせ

-
2022年2月9日: EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

  • EMDBのヘッダファイルのバージョン3が、公式のフォーマットとなりました。
  • これまでは公式だったバージョン1.9は、アーカイブから削除されます。

関連情報:EMDBヘッダ

外部リンク:wwPDBはEMDBデータモデルのバージョン3へ移行します

-
2020年8月12日: 新型コロナ情報

新型コロナ情報

URL: https://pdbj.org/emnavi/covid19.php

新ページ: EM Navigatorに新型コロナウイルスの特設ページを開設しました。

関連情報:Covid-19情報 / 2020年3月5日: 新型コロナウイルスの構造データ

+
2020年3月5日: 新型コロナウイルスの構造データ

新型コロナウイルスの構造データ

関連情報:万見生物種 / 2020年8月12日: 新型コロナ情報

外部リンク:COVID-19特集ページ - PDBj / 今月の分子2020年2月:コロナウイルスプロテーアーゼ

+
2019年1月31日: EMDBのIDの桁数の変更

EMDBのIDの桁数の変更

  • EMDBエントリに付与されているアクセスコード(EMDB-ID)は4桁の数字(例、EMD-1234)でしたが、間もなく枯渇します。これまでの4桁のID番号は4桁のまま変更されませんが、4桁の数字を使い切った後に発行されるIDは5桁以上の数字(例、EMD-12345)になります。5桁のIDは2019年の春頃から発行される見通しです。
  • EM Navigator/万見では、接頭語「EMD-」は省略されています。

関連情報:Q: 「EMD」とは何ですか? / 万見/EM NavigatorにおけるID/アクセスコードの表記

外部リンク:EMDB Accession Codes are Changing Soon! / PDBjへお問い合わせ

+
2017年7月12日: PDB大規模アップデート

PDB大規模アップデート

  • 新バージョンのPDBx/mmCIF辞書形式に基づくデータがリリースされました。
  • 今回の更新はバージョン番号が4から5になる大規模なもので、全エントリデータの書き換えが行われる「Remediation」というアップデートに該当します。
  • このバージョンアップで、電子顕微鏡の実験手法に関する多くの項目の書式が改定されました(例:em_softwareなど)。
  • EM NavigatorとYorodumiでも、この改定に基づいた表示内容になります。

外部リンク:wwPDB Remediation / OneDepデータ基準に準拠した、より強化された内容のモデル構造ファイルが、PDBアーカイブで公開されました。

-
万見文献

EMDB/PDB/SASBDBから引用されている文献のデータベース

  • EMDB/PDB/SASBDBのエントリから引用されている文献のデータベースです
  • Pubmedのデータを利用しています

関連情報:EMDB / PDB / SASBDB / 万見 (Yorodumi) / EMN文献 / 新しいEM Navigatorと万見の変更点

他の情報も見る